U.S. flag An official website of the United States government
  1. Home
  2. About FDA
  3. FDA Organization
  4. Oncology Center of Excellence
  5. A Message to Patients With Cancer and Health Care Providers About COVID-19
  1. Oncology Center of Excellence

A Message to Patients With Cancer and Health Care Providers About COVID-19

The FDA Oncology Center of Excellence recognizes that patients with cancer constitute a vulnerable population at risk of contracting the coronavirus disease (COVID-19). While everyone’s daily lives have been disrupted during the COVID-19 pandemic, the impact may be hardest on those with acute or chronic medical conditions and those with weakened immune systems, such as that caused by cancer and some forms of cancer treatment. 

We also recognize that oncology care providers themselves are faced with immense daily personal and professional challenges. Many of our colleagues are on the front lines of caring for patients with cancer, concerned about protecting the safety of their patients, as well as themselves and their families, while assuring their patients’ access to needed treatment and clinical trials.

In this critical time, we want you to know that we are here for patients with cancer and their health care providers and we will do everything we can to help you through this difficult period. Although our nation’s emphasis is on the need to combat this virus, patients with cancer and their unique needs continue to be a top priority.

To that end, we are working to address critical issues for patients with cancer and their health care providers. Here are a few of our current priorities:

  • We continue to expedite oncology product development. Our staff is teleworking full time and continuing to meet virtually with drug developers, academic investigators, and patient advocates to push forward the coordinated review of drugs, biologics, and devices for cancer.
  • We recognize that modifications may be required in clinical trials. OCE contributed to the FDA Guidance on Conduct of Clinical Trials of Medical Products during the COVID-19 Pandemic.
    • The guidance assists sponsors in assuring the safety of patients involved in clinical trials, keeping patients informed of changes that could impact them, maintaining compliance with good clinical practice, and minimizing risks to trial integrity. The guidance also acknowledges that FDA is aware of these challenges and will work with companies and investigators to maintain patient safety.  
    • We are also meeting with companies to discuss modifications to ongoing and future clinical trials to account for COVID-19 diagnosis, its potential impact on efficacy endpoints, and adjustments to safety monitoring protocols or dosing regimens.  

  • We are innovating how we collect and analyze real-world evidence on patient outcomes to inform our decision-making. OCE has active research collaborations with several data companies to explore new questions brought on by COVID-19 for patients with cancer, including longitudinal studies examining patient demographics and outcomes. Visit our partnerships page to learn more.

  • We continue to process Expanded Access requests for investigational products. Project Facilitate remains open at (240) 402-0004 or [email protected] from 8 a.m. to 4:30 p.m. Eastern time, Monday through Friday, to assist oncology health care providers and regulatory professionals in requesting access to investigational therapies for patients for the treatment of cancer when no satisfactory therapies are available and there is no opportunity for the patient to enroll in a clinical trial.
    • For after-hours emergency requests, contact FDA’s Emergency Call Center at 1-800-300-4374.
    • Health care providers caring for patients with cancer and COVID-19 who are seeking an investigational treatment specifically to treat COVID-19 should contact the Division of Antivirals or CBER directly to request access.
    • Patients and caregivers who need information about accessing investigational therapies may contact the Division of Drug Information at (301) 796-3400 or email [email protected].
  • We are working to anticipate and prevent drug shortages. OCE is in regular contact with the FDA’s drug shortages staff within the Center for Drug Evaluation and Research. FDA is proactively monitoring the supply chain, and OCE will work closely with CDER to prevent or mitigate shortages of oncology drugs that are critical to the treatment of patients with cancer. Shortage notifications and updates may be reported to FDA at [email protected]

Every day, our work in cancer is for you. #OCEWorks4U

Group photo of Oncology Center of Excellence staff


  • We will continue to inform the cancer community. Our work to improve education, resources, outreach, and communications regarding cancer product development continues unabated. We encourage you to follow @FDAOncology on Twitter and check our website for regular updates.

We realize this is a stressful time for all Americans, but especially those with cancer, a life-threatening illness requiring the need for ongoing access to health care services. Here at the OCE, we are committed to patients with cancer and health care providers, and we are here for you at this most difficult time.

Additional Resources:

Back to Top